Vanguard Group Inc. lifted its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,198,796 shares of the biotechnology company's stock after buying an additional 80,302 shares during the period. Vanguard Group Inc. owned about 7.70% of ADMA Biologics worth $312,109,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the company. Lord Abbett & CO. LLC bought a new position in ADMA Biologics in the 3rd quarter valued at approximately $61,858,000. Raymond James Financial Inc. purchased a new position in shares of ADMA Biologics in the fourth quarter worth $19,076,000. EWG Elevate Inc. bought a new position in shares of ADMA Biologics during the fourth quarter valued at $480,000. Allspring Global Investments Holdings LLC boosted its position in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after buying an additional 2,613,482 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in shares of ADMA Biologics during the third quarter valued at $972,000. Hedge funds and other institutional investors own 75.68% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.
View Our Latest Research Report on ADMA
ADMA Biologics Stock Performance
Shares of NASDAQ ADMA traded down $0.54 during midday trading on Tuesday, hitting $17.86. 3,223,735 shares of the company's stock traded hands, compared to its average volume of 3,546,958. The firm has a fifty day moving average of $17.55 and a 200 day moving average of $18.16. ADMA Biologics, Inc. has a 1 year low of $5.90 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market capitalization of $4.22 billion, a price-to-earnings ratio of 63.79 and a beta of 0.53.
ADMA Biologics Company Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
